Our Technology

/Our Technology
Our Technology 2017-05-19T12:55:47+00:00

The Product

The product to be known as the Infrascope™ is a medical device that is capable of providing information for medical diagnostic decisions by healthcare professionals. The product is currently available as a prototype only. The prototype will be used to validate the efficacy of the technology and establish the diagnostic value of the information that can be derived from the unit.

Unlike most diagnostic technologies such as X-Ray Tomography or Echo Ultrasound, the Infrascope™ introduces no energy into the human body to obtain diagnostic information. The Infrascope™ simply detects energy emitted by the human body using proprietary detection technology that is capable of detecting sound within the defined frequency range.

The human ear is typically capable of detecting sound at frequencies from 20 to 20,000 hertz. Infrasound is generically defined as those frequencies below that of unaided human ear detection.

Once the technology has been validated, it will be necessary to conduct a phase of new product development, sometimes referred to as “design for manufacture,” in order to ensure the product is suitably designed and engineered for scale-up to volume manufacture.

The Unmet Need

Each year in the United States, more than 600,000 people die from heart disease. It is the leading cause of death accounting for one in four total mortalities. Of these mortalities, statistics show that some 325,000 people experience their first heart attack and die within approximately one hour of this event due to cardiac arrest. Worldwide these numbers are twenty times larger. (See “The Market.”) An additional 125,000 deaths in the USA are caused by strokes.
Undiagnosed heart disease is a leading cause of death because no cost-effective technology exists in the hands of every front-line medical professional to identify subjects with either early onset or advanced cardiovascular disease states during an annual check-up.
This diagnosis would allow the patient to receive early preventative counseling and recommendations of life-style changes, or in more advanced cases, referral to a cardiologist for timely follow-up care.

The Market

The US medical device industry has an estimated value of $110 billion and is expected to grow to $133 billion by 2016. This industry sector comprises more than 6,500 companies, many of which are medium-sized or small enterprises. It is noteworthy that 80 percent of these companies have fewer than 50 employees, and many, including some of the most innovative and potentially lucrative companies of tomorrow, have little or no sales revenue today.

Infrasonix™ has developed a technology designed to tackle the largest and most costly medical problem in the United States. Cardiovascular disease is a leading cause of death for both men and women in the US. It is responsible for 1 in 4 deaths with over 600,000 deaths annually.

Today, an individual has a heart attack every 34 seconds, and someone dies of a heart-disease-related event every minute. Coronary heart disease alone costs the United States $109 billion dollars each year. Worldwide, cardiovascular disease (CVD) accounted for 17.3 million deaths in 2008 and is predicted to rise to 23.3 million by 2030.

In short, this technology has the potential to bring about a revolution in every area of cardiovascular care, as well as other specialties yet to be identified. At this time, it is difficult to accurately quantify the size of the market for this device. However, in view of the high cost of cardiovascular care highlighted earlier, it is confidently believed that a multibillion dollar global market exists for the product, with revenue models derived from a combination of device sales and annual licensing fees to provide recurring revenue.